Hiring in life sciences? Share your open positions with our professional community. Read more Close

Advertisement

Breakthrough Cutaneous Crohn's Disease Healed With Risankizumab.

Created on 05 Nov 2026

Authors

Kristen Brennan, Daniel Stein, Gretchen M Roth

Published in

WMJ : official publication of the State Medical Society of Wisconsin. Volume 125. Issue 4. Pages 518-520.

Abstract

Extraintestinal manifestations of Crohn's disease are associated with substantial morbidity and commonly present as arthropathies or painful lesions involving the skin, eyes, and mouth. However, they can involve nearly any organ system and do not correlate directly with intestinal inflammation, complicating diagnosis and treatment. As treatment options expand, this article explores the potential role of risankizumab in the treatment of cutaneous Crohn's disease.
A 75-year-old man developed a gluteal fissure consistent with cutaneous Crohn's disease despite longstanding maintenance with adalimumab, an anti-tumor necrosis factor-α (TNF-α) monoclonal antibody. He transitioned to risankizumab, an interleukin-23 (IL-23) inhibitor, with resolution of cutaneous disease involving the gluteal cleft and continued luminal remission.
This case report is the first to demonstrate successful treatment of anti-TNF-resistant cutaneous Crohn's disease with an IL-23 inhibitor. No other published cases were found.
While TNF-α inhibitors remain the standard of care for extraintestinal manifestations of Crohn's, IL-23 inhibitors are a promising therapy option.

PMID:
42981525
Bibliographic data and abstract were imported from PubMed on 05 Nov 2026.

Advertisement

Stats

  • Community rating n/a 0 votes
  • Reviewers' rating n/a 0 votes
  • Your rating

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

  • Recommendations n/a n/a positive of 0 vote(s)
  • Views 11
  • Comments 0

Recommended by

  • No recommendations yet.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.

Advertisement